How molecular profiling of GOG258 is changing advanced endometrial cancer care—insights on POL-E, prognosis, and precision treatment.
In this compelling episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by innovators Dr. Angeles Alvarez Secord and Dr. Aine Clements to discuss high-impact data on endometrial cancer, focusing on the landmark GOG258 trial through the lens of modern molecular classification.
The trio explores how integrating single-gene testing for markers such as POL-E, mismatch repair, and p53 mutations is redefining “high risk,” shifting treatment strategies, and offering new hope for patients with advanced endometrial cancer. Hear first-hand about the years-long research journey, the challenges of trial design, and what practice-changing insights these findings bring to clinicians and patients, particularly regarding treatment de-escalation, prognosis, and precision oncology.
Tune in now to learn how GOG258’s molecular analysis is shaping the future of personalized medicine in uterine cancer care.
Follow Us
Presented by Labcorp Oncology
www.oncology.labcorp.com